Literature DB >> 125463

Plasminogen-plasmin system IX. Specific binding of tranexamic acid to plasmin.

M Iwamoto.   

Abstract

Interactions between tranexamic acid and protein were studied in respect of the antifibrinolytic actions of tranexamic acid. Tranexamic acid did neither show any interaction with fibrinogen or fibrin, nor was incorporated into cross-linked fibrin structure by the action of factor XIII. On the other hand, tranexamic acid bound to human plasmin with a dissociation constant of 3.5 X 10-5 M, which was very close to the inhibition constatn (3.6 X 10-5 M1 for this compound in inhibiting plasmin-induced fibrinolysis. The binding site of tranexamic acid on plasmin was not the catalytic site of plasmin, because TLCK-blocked plasmin also showed a similar affinity to tranexamic acid (the dissociation constant, 2.9-4.8 x 10-5m). in the binding studies with the highly purified plasminogen and TLCK-plasmin preparations which were obtained by affinity chromatography on lysine-substituted Sepharose, the molar binding ratio was shown to be 1.5-1.6 moles tranexamic acid per one mole protein. On the basis of these and other findings, a model for the inhibitory mechanism of tranexamic acid is presented.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 125463

Source DB:  PubMed          Journal:  Thromb Diath Haemorrh        ISSN: 0340-5338


  13 in total

1.  The antifibrinolytic drug tranexamic acid reduces liver injury and fibrosis in a mouse model of chronic bile duct injury.

Authors:  Nikita Joshi; Anna K Kopec; Keara Towery; Kurt J Williams; James P Luyendyk
Journal:  J Pharmacol Exp Ther       Date:  2014-03-14       Impact factor: 4.030

2.  Inhibition of the classical and alternative pathways by amino acids and their derivatives.

Authors:  Y Takada; Y Arimoto; H Mineda; A Takada
Journal:  Immunology       Date:  1978-03       Impact factor: 7.397

Review 3.  Natural inhibitors of fibrinolysis.

Authors:  D Collen
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1980

4.  Genetic polymorphism of human plasminogen.

Authors:  D Raum; D Marcus; C A Alper
Journal:  Am J Hum Genet       Date:  1980-09       Impact factor: 11.025

5.  The ratio of concentrations of aminocaproic acid and tranexamic acid that prevent plasmin activation of platelets does not provide equivalent inhibition of plasmatic fibrinolysis.

Authors:  Vance G Nielsen; Paul M Ford
Journal:  J Thromb Thrombolysis       Date:  2018-10       Impact factor: 2.300

6.  Fibrin(ogen)-independent role of plasminogen activators in acetaminophen-induced liver injury.

Authors:  Bradley P Sullivan; Karen M Kassel; Alice Jone; Matthew J Flick; James P Luyendyk
Journal:  Am J Pathol       Date:  2012-04-13       Impact factor: 4.307

7.  High permissivity of human HepG2 hepatoma cells for influenza viruses.

Authors:  Laurence Ollier; Anne Caramella; Valérie Giordanengo; Jean-Claude Lefebvre
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

8.  Tranexamic acid concentrations associated with human seizures inhibit glycine receptors.

Authors:  Irene Lecker; Dian-Shi Wang; Alexander D Romaschin; Mark Peterson; C David Mazer; Beverley A Orser
Journal:  J Clin Invest       Date:  2012-11-26       Impact factor: 14.808

9.  Tranexamic acid evokes pain by modulating neuronal excitability in the spinal dorsal horn.

Authors:  Nobuko Ohashi; Mika Sasaki; Masayuki Ohashi; Yoshinori Kamiya; Hiroshi Baba; Tatsuro Kohno
Journal:  Sci Rep       Date:  2015-08-21       Impact factor: 4.379

10.  Ultrastructural study of the effects of tranexamic acid and urokinase on metastasis of Lewis lung carcinoma.

Authors:  N Tanaka; H Ogawa; M Kinjo; S Kohga; K Tanaka
Journal:  Br J Cancer       Date:  1982-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.